| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Buclizine hydrochloride (AH-2526, UCB 4445; AH2526;UCB-4445, Buclina, Longifene, Posdel, Vibazine), the hydrochloride salt of buclizine which is used for motion sickness, is a piperazine derivative and a sedating antihistamine with antimuscarinic and moderate sedative action. Buclizine has been used to treat and prevent motion sickness-related nausea, vomiting, and dizziness. It has also been used to treat vertigo in conditions affecting the vestibular apparatus.
| Targets |
Histamine receptor; Cholinergic
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References | |||
| Additional Infomation |
Buclizine dihydrochloride is a hydrochloride salt that is obtained by reaction of buclizine with 2 equivalents of hydrogen chloride. It has a role as a central nervous system depressant, a local anaesthetic, a histamine antagonist, a cholinergic antagonist and an antiemetic. It contains a buclizine(2+).
Buclizine Hydrochloride is the hydrochloride salt form of buclizine, a piperazine histamine H1 receptor antagonist with primarily antiemetic and antivertigo activities. Buclizine binds to and blocks the histamine H1 receptor, thereby preventing the symptoms that are caused by histamine activity. Buclizine exerts its anti-emetic effect by binding to and blocking the muscarinic and histamine receptors in the vomiting center of the central nervous system (CNS). This may prevent activation of the chemoreceptor trigger zone (CTZ) and may reduce nausea and vomiting. |
| Molecular Formula |
C28H35CL3N2
|
|
|---|---|---|
| Molecular Weight |
505.95
|
|
| Exact Mass |
504.186
|
|
| Elemental Analysis |
C, 66.47; H, 6.97; Cl, 21.02; N, 5.54
|
|
| CAS # |
129-74-8
|
|
| Related CAS # |
Buclizine; 82-95-1
|
|
| PubChem CID |
65463
|
|
| Appearance |
White to off-white solid powder
|
|
| Boiling Point |
520.1ºC at 760 mmHg
|
|
| Melting Point |
230-240ºC
|
|
| Flash Point |
268.3ºC
|
|
| Vapour Pressure |
6.44E-11mmHg at 25°C
|
|
| LogP |
8.024
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
2
|
|
| Rotatable Bond Count |
6
|
|
| Heavy Atom Count |
33
|
|
| Complexity |
514
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
CC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl.Cl.Cl
|
|
| InChi Key |
SDBHDSZKNVDKNU-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C28H33ClN2.2ClH/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24;;/h4-16,27H,17-21H2,1-3H3;2*1H
|
|
| Chemical Name |
1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine;dihydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9765 mL | 9.8824 mL | 19.7648 mL | |
| 5 mM | 0.3953 mL | 1.9765 mL | 3.9530 mL | |
| 10 mM | 0.1976 mL | 0.9882 mL | 1.9765 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA